NCT03619902

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Vanda Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.

Detailed description

Single arm, multiple-dose study evaluating the use of imsidolimab for the treatment of GPP.

Conditions

• Generalized Pustular Psoriasis

Interventions

Type	Name	Description
BIOLOGICAL	Imsidolimab	Humanized monoclonal antibody

Timeline

• Start date: 2019-01-30
• Primary completion: 2021-01-20
• Completion: 2021-01-20
• First posted: 2018-08-08
• Last updated: 2025-09-16
• Results posted: 2022-03-29

Locations

13 sites across 4 countries: United States, Poland, South Korea, United Kingdom

Regulatory

• FDA-regulated drug study